TROVAN/ZITHROMAX COMPLIANCE PAK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROVAN/ZITHROMAX COMPLIANCE PAK (TROVAN/ZITHROMAX COMPLIANCE PAK).
Trovafloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication. Azithromycin binds to 50S ribosomal subunit, inhibiting protein synthesis.
| Metabolism | Trovafloxacin: Primarily hepatic via glucuronidation and CYP450 (minimal). Azithromycin: Hepatic metabolism (demethylation); mainly excreted unchanged in bile. |
| Excretion | Trovafloxacin: 43% renal (unchanged), 47% fecal (unchanged + metabolites). Alatrofloxacin: prodrug converted to trovafloxacin. Azithromycin: 12% renal unchanged, 87% biliary/fecal as unchanged drug and metabolites. |
| Half-life | Trovafloxacin: terminal t1/2 ~9-12 hours (allows once-daily dosing). Azithromycin: terminal t1/2 ~68 hours (tissue accumulation enables once-daily 5-day regimen). |
| Protein binding | Trovafloxacin: 70% bound (albumin). Azithromycin: 7-50% (concentration-dependent, mainly to alpha-1-acid glycoprotein). |
| Volume of Distribution | Trovafloxacin: Vd ~1.3 L/kg (extensive tissue distribution). Azithromycin: Vd ~31 L/kg (extreme tissue uptake, e.g., lung, prostate). |
| Bioavailability | Trovafloxacin (oral): 87-95%. Alatrofloxacin (IV): prodrug 100% converted to trovafloxacin. Azithromycin (oral): 37% (reduced by food, take 1h before or 2h after meals); not available IV in this Pak. |
| Onset of Action | Oral trovafloxacin: peak effect in 1-2 hours; IV alatrofloxacin: immediate, conversion complete in 30 min. Azithromycin: peak effect in 2-3 hours oral; IV not in this Pak. |
| Duration of Action | Trovafloxacin: 24 hours (once-daily). Azithromycin: serum levels decline over 5 days; tissue levels persist 5-7 days (beyond last dose). |
| Molecular Weight | Alatrofloxacin: 559.52 Da; Azithromycin: 748.98 Da; combination product weight not applicable. |
Trovan (trovafloxacin/alatrofloxacin) 200 mg IV once daily, then oral trovafloxacin 200 mg once daily; Zithromax (azithromycin) 500 mg IV/oral once daily for 2 days, then 500 mg oral once daily for 7-10 days.
| Dosage form | FOR SUSPENSION, TABLET |
| Renal impairment | Trovan: No adjustment for mild-moderate renal impairment; CrCl <30 mL/min: reduce dose to 100 mg IV/oral once daily. Zithromax: No adjustment for mild-moderate impairment; severe renal impairment (CrCl <10 mL/min): use with caution, no specific dose recommendations. |
| Liver impairment | Trovan: Child-Pugh Class A: no adjustment; Class B/C: reduce dose to 100 mg once daily. Zithromax: Child-Pugh Class A: no adjustment; Class B/C: limited data, use with caution; no specific dose adjustment recommended. |
| Pediatric use | Trovan: Not FDA-approved for children <18 years; avoid use due to arthropathy risk. Zithromax: For children >6 months: 10 mg/kg IV/oral once daily (max 500 mg) for 1 day, then 5 mg/kg once daily (max 250 mg) for 4 days; alternatively, 30 mg/kg as a single oral dose (max 1500 mg) for acute otitis media. |
| Geriatric use | Trovan: No specific dose adjustment; monitor renal function and for QT prolongation. Zithromax: No specific dose adjustment; increased risk of torsades de pointes, monitor ECG and electrolytes; consider lower dose if renal impairment. |
| 1st trimester | No adequate studies; animal studies show embryotoxicity; avoid unless clearly needed. Alatrofloxacin (Trovan) and azithromycin (Zithromax) have differing profiles: azithromycin is generally considered low risk; trovafloxacin is contraindicated in pregnancy due to arthropathy risk. |
| 2nd trimester | Azithromycin generally considered safe if indicated; trovafloxacin contraindicated due to fetal cartilage damage risk. |
| 3rd trimester | Azithromycin generally safe; trovafloxacin contraindicated. |
Clinical note
Comprehensive clinical and safety monograph for TROVAN/ZITHROMAX COMPLIANCE PAK (TROVAN/ZITHROMAX COMPLIANCE PAK).
| Placental transfer | Azithromycin crosses placenta with fetal concentrations approximately 50% of maternal. Trovafloxacin crosses placenta; fetal exposure is significant. |
| Breastfeeding | Azithromycin is excreted in breast milk in low amounts; caution with prolonged use. Trovafloxacin is excreted in breast milk; avoid due to potential adverse effects in nursing infants (e.g., arthropathy). |
■ FDA Black Box Warning
Trovafloxacin: Increased risk of hepatotoxicity, including fatal liver injury, limiting use to life-threatening infections in hospitalized patients.
| Serious Effects |
Hypersensitivity to any component (trovafloxacin, azithromycin, or macrolides/fluoroquinolones)Pregnancy (due to trovafloxacin: skeletal/articular developmental toxicity)Lactation (due to trovafloxacin: potential infant arthropathy)History of tendon disorders related to fluoroquinolones (trovafloxacin)Myasthenia gravis (trovafloxacin may exacerbate)QTc prolongation or concurrent use of drugs prolonging QTc (both components)Hepatic impairment (trovafloxacin-associated hepatotoxicity risk)Known prolonged QT interval or uncorrected electrolyte disturbances
| Precautions | Trovafloxacin: hepatotoxicity with liver failure, CNS effects, QT prolongation. Azithromycin: QT prolongation, hepatotoxicity, severe allergic reactions, Clostridioides difficile diarrhea. |
| Food/Dietary | Azithromycin absorption is reduced by food; take on an empty stomach. Avoid alcohol with trovafloxacin due to potential hepatotoxicity. No specific food interactions with trovafloxacin, but caution with grapefruit juice may apply (limited data). |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) for azithromycin; L4 (Possibly Hazardous) for trovafloxacin; combination should be avoided. |
| Teratogenic Risk | TROVAN (trovafloxacin) is pregnancy category C; animal studies show fetal toxicity but no well-controlled human studies. Avoid in first trimester due to fluoroquinolone class effect on cartilage. ZITHROMAX (azithromycin) is pregnancy category B; no evidence of fetal harm in animal studies, but human data limited. Preferred over fluoroquinolones in pregnancy if indicated. |
| Fetal Monitoring | Monitor maternal liver function and ECG (trovafloxacin risk of hepatotoxicity and QT prolongation). Fetal ultrasound for anomalies if first-trimester exposure to trovafloxacin. Assess infant for jaundice, diarrhea, and somnolence. |
| Fertility Effects | Azithromycin: No documented effect on fertility in animal studies. Trovafloxacin: High doses in animals reduced spermatogenesis; clinical relevance unknown. Use caution in couples planning pregnancy. |
| Clinical Pearls | Trovan (trovafloxacin) is rarely used due to hepatotoxicity; Zithromax (azithromycin) is preferred. This combo pack is obsolete; never prescribe trovafloxacin first-line. Azithromycin prolongs QTc; check for interacting drugs. |
| Patient Advice | Take azithromycin on an empty stomach (1 hour before or 2 hours after meals) unless directed otherwise. · Complete the full course even if you feel better. · Avoid taking antacids containing aluminum or magnesium within 2 hours of azithromycin. · Report any signs of liver injury (jaundice, dark urine, abdominal pain) immediately if taking trovafloxacin. · Do not take this medication if you have a history of QT prolongation or are taking certain heart rhythm medications. |